Abingworth
Allison Jeynes-Ellis, MD, FFPM (UK), is a clinician with more than 25 years of senior leadership experience in the pharmaceutical industry. As CEO of our portfolio company Avillion LLP, which specializes in co-development and financing of late-stage pharmaceuticals, Allison is responsible for identifying high-potential opportunities to fund programs to approval. Previously, she led development at Wyeth, BMS, and Novartis and has secured numerous U.S. and EU drug approvals. Allison serves as a non-executive director of Agenus Inc and Anaveon.
This person is not in the org chart
This person is not in any offices
Abingworth
1 followers
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors. Supporting its portfolio companies with a team of 25 at offices in London, Menlo Park, and Boston, Abingworth has invested in 151 life science companies, completed 65 IPOs and 42 mergers and acquisitions.